FDA Grants Fast Track Designation for Reneo Pharma’s Mavodelpar (REN001) for LCHAD Deficiency Treatment
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing and commercialising therapies for patients with rare genetic mitochondrial diseases granted Fast Track design ...